NCT01817868View on ClinicalTrials.gov

Comparison of Efficacy, Safety and Costs of Recombinant FVIII Products Between On-demand and Secondary Prophylaxis Groups in Haemophilia A Patients

CompletedOBSERVATIONAL
Enrollment

73

Participants

Timeline

Start Date

January 4, 2013

Primary Completion Date

July 16, 2018

Study Completion Date

May 23, 2019

Conditions
Hemophilia
Interventions
OTHER

Recombinant Factor VIII (Kogenate, BAY14-2222)

All dosage, frequency and duration for drugs will be under the decision of the treating physician.

Trial Locations (1)

Unknown

Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01817868 - Comparison of Efficacy, Safety and Costs of Recombinant FVIII Products Between On-demand and Secondary Prophylaxis Groups in Haemophilia A Patients | Biotech Hunter | Biotech Hunter